Pharvaris to report topline Phase 3 results of deucrictibant in Q4

Pharvaris (PHVS) updated the guidance for the disclosure of topline data from the ongoing RAPIDe-3 pivotal Phase 3 study evaluating deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks. Pharvaris anticipates announcing topline data from RAPIDe-3 in Q4 of 2025 and, pending positive data, expects to submit a New Drug Application, or NDA, with the FDA in the first half of 2026. RAPIDe-3 is a global Phase 3 study evaluating deucrictibant immediate-release capsule for the on-demand treatment of angioedema attacks in approximately 120 adult and adolescent participants with HAE, including forms with C1 inhibitor deficiency and forms with normal C1INH. The primary endpoint is time to onset of symptom relief. Other endpoints include time to End of Progression in attack symptoms, substantial symptom relief, complete symptom resolution and proportion of complete symptom resolution achieved with one dose of deucrictibant.